Adalimumab Injection (Junmaikang) – 40?mg – Low price wholesale comparison

Adalimumab Injection (Junmaikang) – 40?mg – Low price wholesale comparison

$2.00

Adalimumab Injection (Junmaikang) offers 40?mg of TNF?? monoclonal antibody in a 0.8?mL prefilled syringe. Jointly developed by Junshi Biosciences and Mabwell, produced by Suzhou Zhonghe Biomed Tech Co., Ltd. NMPA-approved under S20220008. Intended strictly for laboratory research use. Wholesale and retail orders supported.?Please consult staff for price, other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

描述

Junmaikang® is a biosimilar of adalimumab, a fully human monoclonal antibody targeting TNF??, approved by China’s NMPA (approval number S20220008) . Manufactured by Suzhou Zhonghe Biomed Tech Co., Ltd., it mirrors the therapeutic action of Humira®, and is widely used in research exploring autoimmune pathways, inflammation, and immune modulation.

Available as a single-use 0.8?mL prefilled syringe containing 40?mg adalimumab, it supports in vitro and in vivo laboratory research—such as cytokine inhibition assays, arthritis models, immune cell signaling pathways, and TNF?? neutralization studies.


Adalimumab Injection Product Specifications

Parameter Details
Product Name Adalimumab Injection (Junmaikang)
Generic Name Adalimumab (TNF?? Monoclonal Antibody Biosimilar)
CAS Number 331731?18?1
Molecular Formula Protein (monoclonal antibody ~148?kDa)
Dosage Form Prefilled syringe
Strength 40?mg in 0.8?mL
Packaging 1 syringe per box
Approval Number S20220008 (China NMPA)
Product Code 86981823000043
Manufacturer Suzhou Zhonghe Biomed Tech Co., Ltd.
Intended Use Laboratory research only
Storage Conditions Refrigerate at 2–8?°C; protect from light
Barcode (Not specified)

Adalimumab Injection Mechanism & Research Applications

Adalimumab (Junmaikang) functions by binding to TNF??, blocking its interaction with cell receptors, thereby inhibiting inflammatory signaling cascades. As an NMPA-approved biosimilar, it’s suitable for:

  • TNF?? neutralization assays

  • Autoimmune disease models (arthritis, colitis)

  • Inflammatory cytokine modulation studies

  • Immunology and cell signaling research

  • Comparative analysis with reference adalimumab


Adalimumab Injection Observed Effects & Preclinical Notes

While primarily a research agent, adalimumab has shown:

  • In vivo reduction of TNF?? levels and inflammatory markers

  • Modulation of immune cell function

  • Minimal immunogenic responses in validated animal models

Researchers should monitor dose responses and manage biosafety per institutional guidelines.


Safety & Handling Guidelines

  • Use Restriction: Laboratory research only — not for human or veterinary use

  • PPE Required: Gloves, lab coat, safety goggles

  • Storage: Keep refrigerated at 2–8?°C; avoid freezing and light exposure

  • Disposal: Dispose as biohazardous material per institutional protocols


Research Use Disclaimer

This product is strictly for laboratory research use only. It is not intended for human or veterinary treatment, clinical diagnosis, or use. Misuse may result in serious legal and health consequences. Handle according to biosafety and institutional regulations.

其他信息

重量 1 公斤
尺寸 26 × 23 × 26 厘米

评价

目前还没有评价

成为第一个“Adalimumab Injection (Junmaikang) – 40?mg – Low price wholesale comparison” 的评价者

您的邮箱地址不会被公开。 必填项已用 * 标注

EMI Options

Select at least 2 products
to compare